Work

Topical ruxolitinib for treatment-induced vitiligo in a patient with metastatic melanoma

Year: 2024

Type: article

Abstract: Vitiligo is a well-known side effect in patients undergoing treatment for melanoma with either anti-PD-1 immunotherapy or B-Raf (BRAF)/mitogen-activated protein kinase (MEK)-directed targeted therapy.1 Its occurrence is related to a favorable tumor response and prolonged survival.2,3 Spontaneous repigmentation is occasionally observed in association with tumor relapse.4 Otherwise, the depigmentation persists and may cause distress to the patients concerned.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2024.11.002

Authors: Alpaslan Tasdogan, Dirk Schadendorf, Selma Ugurel

Institutions: Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, University of Duisburg-Essen

Language: English

Topic: melanin and skin pigmentation

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $750